S U M M A R Y Sera from multiple sclerosis patients with relapsing-remitting disease and normal subjects were tested for antibody to myelin basic protein by a sensitive radioimmunoassay. The results showed a marginally decreased titre in multiple sclerosis superimposed on a seasonal variation. There was no correlation with the clinical state of the patients. Results are discussed briefly in relation to humoral antibody function in multiple sclerosis and experimental autoimmune encephalitis.
Evidence for increased circulating antibody to whole brain and a variety of brain fractions by various methods in multiple sclerosis (MS) has been sought for many years (reviewed by Lumsden, 1972 ) to try to establish a possible autoimmune or immune-mediated pathogenesis for the disease (Alvord, 1970; McAlpine et al., 1972) . The results of previous studies have ranged from specific elevation in MS, significant elevation but also in a number of other neurological diseases, to results where patients and control subjects did not differ (Lumsden, 1972; Caspary, 1977) .
At present. experimental allergic encephalomyelitis (EAE), especially in the chronic (Stone and Lerner, 1964) and relapsing (Wisniewski and Keith, 1977) forms, presents the best animal model for the disease in man. Therefore, the specific antigen capable of initiating EAE, myelin basic protein (MBP), is the antigen of choice in the search for antibody. In animals immunised with CNS antigens to produce EAE, specific binding has been shown by radioimmunoassay by several workers (Kibler and Barnes, 1962; Caspary, 1966; Kies et al., 1975; McFarlin et al., 1975) but similar investigations in MS patients (Caspary, 1966; Lisak et al., 1968; Lennon and Mackay, 1972) failed to demonstrate elevated antibody response. The role of such antibody remains obscure.
In the present work a further attempt has been made to seek antibody to MBP in patients with multiple sclerosis over time, using a very sensitive and specific radioimmunoassay.
Patients and methods
The patients in the MS group all had definite relapsing-remitting disease. The women in the group had a mean age of 37.9 yr and the men a mean age of 34.8 yr, with a sex ratio of 3: 2. The mean age of the control subjects was 35.6 yr for women, 38.8 yr for men, with a sex ratio of 1: 1.
The patients were assessed at regular intervals, and blood was taken, and separated, and the serum stored at -700C.
Specific binding of MBP to serum was measured by radioimmunoassay using the method of Cohen et al. (1975) McDermott and Caspary (1975) .
Results
The overall results are shown in Fig. 1 (Fig. 2) .
Discussion
The results of the present study indicate a marginally reduced serum antibody response to MBP in patients with multiple sclerosis compared with normal subjects. However, no gross changes were seen in agreement with earlier work (Lisak, 1975; Caspary, 1977) . As the present findings are superimposed on a seasonal variation their precise meaning must, therefore, contain an element of uncertainty. Interpretation in pathogenetic terms is also impeded by the gross overlapping of results between MS patients and normal subjects.
In general, our limited knowledge of the function of humoral factors in MS or even in its experimental "model" (EAE) makes it difficult to assess our findings; some of the known properties are described to clarify the overall picture. Serum in the experimental disease cannot be used to transfer the disease, though passive transfer is readily achieved with cells (reviewed by Raine, 1976) . Protection by serum against EAE was shown by Paterson and Harwin (1963) as well as a blocking action of serum on encephaligenicity of MBP (Bergstrand, 1976) the human disease or its treatment. Damaging effects such as myelinotoxicity and transmission block in cultures (Bornstein, 1973) have not to date been seen in vivo. Antimyelin antibody has been found by immunofluorescence in MS, amyotrophic lateral sclerosis, and in the Guillain-Barre syndrome, and appears to be specific to myelin. A lesser degree of binding occurs in normal subjects . Perhaps the most promising role for antibody is that shown by Brosnan et al. (1977) in their morphological observations on demyelination in the rabbit retina. They concluded that demyelination followed an antibody-mediated cytotoxic reaction. It, therefore, becomes apparent that conventional methods for antibody detection with MBP, the antigen of EAE but only presumptive in MS, may fail to detect a disease-specific change. In the first instance, the antigen may be different and, secondly, functional assays may be needed to detect the relevant humoral factor (antibody).
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